SETTING: National Center for Tuberculosis and Lung Diseases (NCTLD), Tbilisi, Georgia.OBJECTIVE: To determine clinical outcomes of patients with tuberculous meningitis (TBM) treated with an intensified regimen including a fluoroquinolone (FQ) and an injectable agent.DESIGN: Prospective cohort of patients aged ≥16 years initiating treatment for TBM at the NCTLD from January 2018 to December 2019. Treatment outcomes and neurologic disability at 1, 6 and 12 months after treatment initiation were assessed.RESULTS: Among 77 patients with median follow-up time of 363 days (IQR 269–374), 97% received a FQ, 62% an injectable agent, 44% linezolid and 39% a carbapenem. Fifty-seven patients (74%) successfully completed treatment, 2 (2.6%) had treatment failure, 6 (7.8%) died, and the remainder (12%) were lost to follow up. Among 11 patients treated for multidrug-resistant TBM, the median follow-up time was 467 days and one patient (8%) died. Regarding neurologic outcomes, 14/76 (18%) patients had Modified Rankin Scores of 0 at baseline, improving to 85% (56/66) and 94% (47/50) at 6 and 12 months, respectively.CONCLUSION: Intensified multidrug treatment regimens including a FQ and an injectable agent in all patients and newly implemented drugs in patients with multidrug-resistant TBM resulted in low mortality and favorable neurologic outcomes.
14 January 2021 in Monaldi Archives for Chest Disease
Tuberculosis treatment is challenging, especially among people with drug-resistant forms of tuberculosis. The introduction of fully oral modified short treatment regimen has a great potential to shorten duration of treatment, improve safety and ultimately increase treatment success rate. In 2019 Georgia has piloted the modified fully oral shorter treatment regimen in a routine programmatic condition. Our study aimed to evaluate effectiveness and safety of the modified shorter treatment regimen in Georgia among the first 25 consecutively enrolled patients with rifampicin-resistant tuberculosis with proven sensitivity to fluoroquinolone and without prior exposure to second-line tuberculosis drugs. Regimen consisted of 9-month daily administration of bedaquilline, linezolid, levofloxacin, clofazimine and cycloserine. Study patients were enrolled between March-August 2019. We used a national electronic surveillance system, medical records and active TB drug-safety monitoring and management database to extract study related data. The mean age of the study participants was 48 years, 68% were male, 8% were HIV positive, 16% had diabetes and 12% tested positive for hepatitis C infection. The median time to culture conversion among 16 patients who were culture positive at treatment initiation was 1.0 (95% CI: 1.0-2.0) month. Of those, by the end of treatment 15 patients converted to negative. Out of the 25 patients in the study cohort 22 (88%) had successful treatment outcome, one patient (4%) died and two (8%) were lost to follow up. The regimen was largely well tolerated. Three patients (12%) experienced serious adverse events, of which in two cases were possibly related to TB drugs in the regimen. Seven patients developed adverse events of interest in eight instances, including musculoskeletal (twice), psychiatric, gastrointestinal disorders, hepatotoxicity, peripheral neuropathy, cardiotoxicity and myelosuppression (once each). In four patients (16%) the duration of the treatment was extended beyond nine months due to insufficient radiological improvements. Our findings demonstrate that good treatment outcomes are achievable in people with fluoroquinolone-sensitive tuberculosis within routine programmatic conditions using fully oral modified short treatment regimen. The extensive use of fully oral modified shorter treatment regimen in Georgia and other high priority countries in the World Health Organization European Region is warranted.
Tuberculosis (TB) remains a major public health concern. Improving TB control programmes and treatment success rates requires a deeper understanding of the factors that determine disease presentation and patient treatment outcomes. While the demographic and clinical factors influencing treatment outcomes are well documented, the role of bacterial genetics remains limited. In this study, we analyzed the Mycobacterium tuberculosis complex (MTBC) genomes and the associated clinical data from 4,536 TB patients in the country of Georgia covering a period of 13 years. Multivariable modelling confirmed the role of known demographic and clinical factors such as sex, age, body mass index (BMI) and comorbidities in determining treatment outcomes, as well as the efficacy of novel TB treatments containing bedaquiline. In addition, we found that some bacterial variables, including the MTBC lineage, the specific mutations conferring resistance to rifampicin and fluoroquinolones, as well as a high bacterial burden were associated with unfavorable outcomes. GWAS analyses revealed no genetic mutations in the bacteria other than known drug resistance-conferring mutations to be associated with treatment outcomes. However, we found that mutations in the bacterial gene sufD were linked to cavitary disease. Additionally, we observed that mutations in sufD, mutations conferring resistance to rifampicin and fitness compensatory mutations were associated with the bacterial burden within patients. We conclude that both patient and bacterial factors determine disease presentation and clinical outcomes in TB.
Introduction: Susceptibility testing of new and repurposed anti-TB drugs in Georgia in 2020 demonstrated that, 28% of pre-XDR-TB cases had additional resistance to one of the most effective “Group A” drugs. The aim: of the study was to investigate in vitro inhibitory effect of Moxifloxacin (Mfx) and silver nanoparticle (AgNPs ) composite on Mfx resistant ( Mfx/R-TB) Mycobacterium tuberculosis (MTB) strains. Materials and Methods: Standard dose of Mfx and 20 nm AgNPs [of 6 different concentrations: 0.25%; 0.5%; 1%; 2.5%; 5%; 10%] were added to already grown 40 resistant Mfx/R-TB cultures. The control group consisted of 35 Mfx/R isolates, to which only solutions of AgNPs of identical concentrations were added. The inhibitory effect of different concentrations of Mfx and AgNPs was evaluated according to MTB growth rate using the BACTECTM MGIT 960TM TB System. Results: In vitro usage of nanocomposite with standard dose of Mfx and 20 nm 2.5% AgNPs solution showed minimal inhibitory effect on Mfx/R-MTB strains, while using with standard dose of Mfx or solely, and usage of 5,0% solution demonstrated minimal bactericidal effect. In vitro usage of standard dose of Mfx with addition of 20 nm 2.5% AgNPs nanocomposite solution increased minimal inhibitory effect by 16.7% on Mfx/R-MTB strains (86.7%) compared to using only 20 nm 2.5% solution of AgNPs (70%). Conclusion: The study of the effectiveness of the nanocomposite on pre-XDR MTB strains in vitro showed potential influence of AgNPs on overcoming resistance against Mfx.